NCT04553887Unknown2 期
Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2020年11月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 53
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
This is a Phase 2 study to evaluate the efficacy and the safety/ tolerability of Almonertinib in NSCLC patients with uncommon EGFR Mutation or EGFR exon 20 insertion mutations. Patients with EGFR exon 20 insertion mutations have to had at least one prior systemic treatment for locally advanced or metastatic NSCLC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-75years#ECOG PS#0-2#Life expectancy of more than 3 months#with measurable lesion ( RECIST1.1).
- •Cohort A: Patients with EGFR exon 20 insertion, failure of first-line standard chemotherapy, or intolerance to chemotherapy Cohort B: Patients with uncommen EGFR mutations but without exon 19 deletion, L858R, T790M, and exon 20 insertion
- •≥1 target lesion that has not received radiotherapy in the past 3 months and can be accurately measured in at least 1 direction#Previously received radiation therapy, but the radiotherapy area must be <25% of the bone marrow area, and radiation therapy must have closed for at least≥4 weeks at the time of enrollment.
- •Main organs function is normal.
- •Signed and dated informed consent.
排除标准
- •Patient has had previous treatment with Pyrotinib, Poziotinib or any other EGFR or HER2 exon 20 insertion mutation-selective tyrosine kinase inhibitor (TKI) prior to study participation. The currently approved TKIs (ie, erlotinib, gefitinib, afatinib, osimertinib) are not considered to be exon 20 insertion-selective and are permissible
- •Patients with EGFR 19 exon deletion mutation, 21 exon L858R mutation or 20 exon T790M mutation.
- •Small cell lung cancer (including mixed small cell and non-small cell lung cancer);
- •Cohort A: Patients who had previously used the third generation of EGFR-TKI (including Almonertinib, Osimertinib, etc.) Cohort B: Patients who had previously used EGFR-TKI
- •Patients who planned to receive systemic anti-tumor therapy within 4 weeks prior to allocation or during the course of this study, including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or receiving the Mitomycin C 6 weeks prior to medication). Extra-field radiotherapy (EF-RT) was performed 4 weeks prior to allocation or restricted radiotherapy for assessing tumor lesions within 2 weeks prior to allocation
- •With kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus)
- •Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to Almonertinib
- •History of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency disease, or history of organ transplantation; active infection including hepatitis B (HBV DNA level ≥1000 copies /mL), hepatitis C and human immunodeficiency virus (HIV); Severe acute or chronic infections requiring systemic treatment
- •Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial
- •Known history of neurological or psychiatric disease, including epilepsy or dementia
- •Has a history of malignant tumors. Except for patients with cutaneous basal cell carcinoma, superficial bladder cancer, cutaneous squamous cell carcinoma or orthotopic cervical cancer who have undergone curative treatment and have no disease recurrence within 5 years after the start of treatment
- •Respiratory syndrome (dyspnea≥CTC AE 2), severe pleural effusion, ascites, pericardial effusion
- •Patient has had other malignancies within the past 3 years, except for stable non-melanoma skin cancer, fully treated and stable early stage prostate cancer or carcinoma in situ of the cervix or breast without need of treatment
- •Patient is pregnant or breast-feeding
- •Judgment by the investigator that should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements
研究组 & 干预措施
Cohort 1
Experimental
Previously treated NSCLC patients with EGFR exon 20 insertion mutantion
干预措施: Almonertinib (Drug)
Cohort 2
Experimental
NSCLC Patients with uncommon EGFR Mutation
干预措施: Almonertinib (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: To evaluate objective response rate 6-8 weeks after the initiation of Almonertinib
The proportion of subjects who achieve Complete Response (CR) and Partial Response (PR) by the best response from the first dose of Almonertinib to the end of study.
次要结局
- Progression Free Survival(30 months)
- Overall Survival(30 months)
- Duration of Response(30 months)
- Safety and Tolerability(30 months)
- Disease Control Rate(30 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT01233687Ahmad Tarhini49
招募中
2 期
Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)Non-Small-Cell Lung CancerNCT05255406Fudan University62
Unknown
2 期
EGFR Mutation Positive NSCLC Patients With Gefitinib and ThalidomideNSCLC Stage IVChemotherapy EffectNCT03341494Fujian Cancer Hospital128
尚未招募
2 期
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung CancerAdvanced Non Small Cell Lung CancerNCT04755738Qianfoshan Hospital234
撤回
1 期
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerNSCLCNCT05693090Kura Oncology, Inc.